SAN DIEGO, May 9, 2011 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a therapeutic oncology company developing innovativemedical approaches to treat solid tumor cancers with unmet medical needs, announced today the cancer therapy company's tumor-destroying, tissue-sparing drug/device technology was profiled in Medical Device Daily, the news source for the high-tech medical
The article noted that OncoSec is leveraging the successful treatment of cancers in early and late stage clinical trials of more than 400 patients to advance its proprietary drug technology delivery system, which enables highly targeted delivery of chemotherapy agents and DNA-based immunotherapies into solid tumors.
The article quoted OncoSec's CEO, Punit Dhillon, who said: "...[OncoSec] is not your typical startup because we're leveraging a lot of historical and clinical data, along with clinical experience."
Dhillon foresees a large market opportunity for the OncoSec drug/device treatment system: "Our conservative estimate is at least four million people in the U.S. Where the larger market lies is in emerging markets. That could exponentially increase [the market]," he said.
The full article can be found at: http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=75423
About OncoSec Medical Inc.
OncoSec Medical's (OTCBB: ONCS) novel ElectroOncology therapies combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents achieves selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. More information is available at www.oncosec.com.
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
SOURCE OncoSec Medical Incorporated
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All